Cancers in Togo from 1984 to 2008: Epidemiological and Pathological Aspects of 5251 Cases by Amégbor, Koffi et al.
Hindawi Publishing Corporation
Journal of Cancer Epidemiology
Volume 2011, Article ID 319872, 7 pages
doi:10.1155/2011/319872
Clinical Study
Cancersin Togo from 1984 to 2008: Epidemiologicaland
Pathological Aspects of 5251 Cases
Kofﬁ Am´ egbor,1,2 TchinDarre,1 Kofﬁ Didier Ay´ ena,3 EssohanaPadaro,4 Kodjo Tengu´ e,5
AnaniAbalo,5 andGadoNapo-Koura1
1Laboratoire d’Anatomie et Cytologie Pathologiques, CHU Tokoin, Lom´ e, Togo
2Facult´ e Mixte de M´ edecine et de Pharmacie, Universit´ ed eL o m ´ e, BP 1515, Lom´ e, Togo
3Service d’Ophtalmologie, CHU Kara, Togo
4Laboratoire d’H´ ematologie Clinique, CHU Tokoin, Lom´ e, Togo
5Pavillon Militaire, Service de Chirurgie, CHU Tokoin, Lom´ e, Togo
Correspondence should be addressed to Koﬃ Am´ egbor, f6kamegbor@yahoo.fr
Received 5 April 2011; Revised 26 July 2011; Accepted 10 August 2011
Academic Editor: Carmen J. Marsit
Copyright © 2011 Koﬃ Am´ egbor et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. To describe the epidemiological and histological aspects of cancers in Togo. Materials and Methods.W em a d ea
retrospective review of the epidemiological and pathological features of cancers observed from 1984 to 2008 at the laboratory
of pathology of CHU-TOKOIN in Lom´ e, Togo. Results. During our study period, we found 5251 cases of cancers with an annual
averagefrequencyof210cases.Thesexratio,male/female,was0.9andtheaverageageofoccurringwas45.3years.Thisaverageage
was 46.9 years for men and 43.8 years for women. The mostfrequent cancers for men were prostatecancer (12.9%),nonmelanoma
skincancer(10.4%),andgastriccancer(10.3%).Forwomenitwasbreastcancer(27.1%),cervixcancer(11.2%)andnon-Hodgkin
lymphoma (6.3%). Histologically, it was carcinomas in 68.1% of the cases, sarcomas in 11% of the cases and non-Hodgkin
lymphomas in 12.6% of the cases. Children cancers were primarily Burkitt lymphoma (27.9% of cases) and retinoblastoma (8.5%
ofcases).Conclusion.ThisstudyshowsthatcancersarefrequentinTogoandemphasizesonthenecessityofhavingacancerregister
for the prevention and the control of this disease in Togo.
1.Introduction
T h eg l o b a lb u r d e no fc a n c e rw e i g h sm o r ee a c hd a y .C u r -
rently, there are more than 22 million cases in the world
with more than half in developing countries [1, 2]. Togo,
followingtheexampleofmostcountriesintheWHOAfrican
region,hasnodataontheextentandglobalcharacteristicsof
cancer [3].
The aim of our study was to describe the epidemiological
and histopathological aspects of cancers diagnosed in the
laboratory of pathology of CHU-TOKOIN in Lom´ e, in order
to promote the establishment of a cancer register in Togo.
Togo is indeed a small country in the West African coast of
56600km2 with 6,145,000 inhabitants. It has a population
growth rate of 2.7% and life expectancy at birth is 54 years.
The population is very young (60% under 20 years and only
3.1% over 64 years) and the seroprevalence rate of HIV
passed from 6% in 2000 to 4.5% in 2004 [4]. The economy
of the country relies on agriculture, breeding, and export of
phosphate.
2.MaterialsandMethods
This was a retrospective and descriptive study carried on
all cancer cases diagnosed from January 1984 to December
2008 (25 years) in the only laboratory of pathology of Togo,
located inside CHU-TOKOIN in Lom´ e( T o g o ) .T h e s ec a s e s
were compiled from records of that laboratory. The study
materialconsisted ofbiopsies andsurgicalspecimensﬁxedin
formalin at 10% and came from various medical structures
in Togo. These samples were processed by conventional
histological techniques. Studied variables were frequency,
sex, age, cancer site, and its histological nature. For the2 Journal of Cancer Epidemiology
Table 1: Distribution of cancers by site and sex.
ICD-10 Site Male % Female % Both sexes %
Nb∗∗ of cases Nb∗∗ of cases Nb∗∗ of cases
C0–C06 Mouth 80 3.1 39 1.5 119 2.3
C07-C08 Salivary gland 77 3.0 39 1.5 116 2.2
C9–C14 Pharynx 52 2 22 0.8 74 1.3
C15 Oesophagus 129 5.0 49 1.8 178 3.4
C16 Stomach 264 10.3 115 4.3 379 7.2
C17 Small intestine 19 0.7 14 0.5 33 0.6
C18–C21 Colon, rectum, anus 115 4.5 61 2.2 176 3.4
C22 Liver 74 2.9 42 1.6 116 2.2
C23-C24 Gallbladder, and so forth. 3 0.1 5 0.2 8 0.2
C25 Pancreas 16 0.6 5 0.2 21 0.4
C30-C31 Nose, sinuses, and so forth. 31 1.2 10 0.4 41 0.8
C32 Larynx 95 3.7 12 0.4 107 2.0
C33-C34 Trachea, bronchus and lung 40 1.6 12 0.4 52 1.0
C38 Pleura 23 0.9 31 1.2 54 1.0
C40-C41 Bone 160 6.2 99 3.7 259 4.9
C43 Melanoma of the skin 48 1.9 25 0.9 73 1.4
C44 Other skin cancers 268 10.4 134 5.0 402 7.6
C45 Mesothelioma 2 0.0 5 0.2 7 0.2
C46 Kaposi’s sarcoma 92 3.6 133 5.0 225 4.3
C49 Other soft tissue 13 0.5 14 0.5 27 0.5
C50 Breast 25 1.1 729 27.1 754 14.4
C51 Vulva — — 20 0.7 20 0.4
C52 Vagina — — 27 1.0 27 0.5
C53 Cervix — — 302 11.2 302 5.8
C54 Uterus — — 112 4.2 112 2.1
C56 Ovary — — 132 4.9 132 2.5
C57 Fallopian tube — — 3 0.1 3 0.1
C58 Placenta — — 43 1.6 43 0.8
C60 Penis 13 0.5 — — 13 0.2
C61 Prostate 332 12.9 — — 332 6.3
C62 Testis 21 0.8 — — 21 0.4
C64 Kidney 29 1.1 22 0.8 51 1.1
C65 Renal pelvis 4 0.2 1 0.0 5 0.1
C67 Bladder 43 1.7 21 0.8 64 1.2
C68 Ureter 1 0.0 0 0.0 1 0.0
C69 Eye 70 2.7 62 23 132 2.5
C70–C72 Brain, nervous system 2 0.1 4 0.1 6 0.1
C73 Thyroid 23 0.9 62 2.3 85 1.6
C76 Other and unspeciﬁed 13 0.5 9 0.3 22 0.4
C77–C80 Metastasis 55 2.1 41 1.5 96 1.9
C81 Hodgkin disease 62 2.4 30 1.1 92 1.8
C82–C85 Non-Hodgkin Lymphoma 237 9.2 170 6.3 407 7.8
C90 Myeloma 5 0.2 1 0.0 6 0.1
C91–C95 Leukaemia 29 1.1 29 1.1 58 1.1
All sites 2565 100 2686 100 5251 100
Nb∗∗:N u m b e r .Journal of Cancer Epidemiology 3
Table 2: Distribution of cancers by site and age in men.
ICD-10 Site Unk 0–14 15–24 25–34 35–44 45–54 55–64 65+ All %
C0–C06 Mouth 1 1 3 7 12 20 22 14 80 3.1
C07-C08 Salivary gland 1 6 10 12 12 9 16 11 77 3.0
C9–C14 Pharynx 1 3 4 3 6 12 7 16 52 5.2
C16 Stomach 8 1 9 16 48 64 44 74 264 10.3
C17 Small intestine 0 1 5 2 3 0 4 4 19 0.7
C18–C21 Colon, rectum, anus 0 3 5 12 25 31 20 19 176 4.5
C 2 2 L i v e r 1 4 52 0 1 1 1 79 77 4 2 . 9
C 2 3 - C 2 4 G a l l b l a d d e r , a n d s o f o r t h . 000021003 0 . 1
C 2 5 P a n c r e a s 00122263 1 6 0 . 6
C30-C31 Nose, sinuses, and so forth. 1 1 5 2 3 6 5 8 31 1.2
C32 Larynx 1 0 0 4 16 38 25 11 95 3.7
C 3 3 - C 3 4 T r a c h e a , b r o n c h u s a n d l u n g 0 0 3 4 71 35 84 0 1 . 6
C 3 8 P l e u r a 00221666 2 3 0 . 9
C40-C41 Bone 2 51 21 17 15 25 10 19 160 6.2
C43 Melanoma of the skin 0 0 0 7 11 8 8 14 48 1.9
C44 Other skin cancers 5 4 4 66 50 48 30 31 268 10.4
C 4 5 M e s o t h e l i o m a 000100102 0 . 0
C46 Kaposi’s sarcoma 3 10 3 16 21 13 9 17 92 3.6
C 4 9 O t h e r s o f t t i s s u e 15300040 1 3 0 . 5
C 5 0 B r e a s t 0002452 1 2 2 5 1 . 1
C 6 0 P e n i s 00001183 1 3 0 . 5
C61 Prostate 3 0 0 0 2 26 73 228 332 12.9
C 6 2 T e s t i s 06321324 2 1 0 . 8
C64 Kidney 0 11 5 2 0 3 5 3 29 1.1
C 6 5 R e n a l p e l v i s 000002204 0 . 2
C67 Bladder 0 1 0 1 15 5 10 11 43 1.7
C 6 8 U r e t e r 100000001 0 . 0
C 6 9 E y e 12 49 71 17 7 47 0 2 . 7
C 7 0 – C 7 2 B r a i n , n e r v o u s s y s t e m 000101002 0 . 1
C 7 3 T h y r o i d 00147443 2 3 0 . 9
C76 Other and unspeciﬁed 0 0 1 2 3 3 2 2 13 0.5
C 7 7 – C 8 0 M e t a s t a s i s 3 0 4 6 82 07 75 5 2 . 1
C81 Hodgkin disease 0 23 17 9 7 3 2 1 62 2.4
C 8 2 – C 8 5 N o n - H o d g k i n L y m p h o m a 4 6 13 82 93 13 81 81 8 2 3 7 9 . 2
C 9 0 M y e l o m a 000102205 0 . 2
C 9 1 – C 9 5 L e u k a e m i a 12355454 2 9 1 . 1
All sites 39 219 195 268 353 482 413 596 2565 100
distribution of diﬀerent anatomical sites of cancers we used
the international classiﬁcation of diseases adopted by WHO
in 2002 (ICD-10). Statistical processing and data analysis
were performed by using SPSS software.
3. Results
3.1. Epidemiological Aspects. We have collected during our
study period 5251 cases of cancer histologically conﬁrmed,
with a yearly average of 210 cases. We observed a decrease
of cancer incidence in the last ten years (from 1999 to 2008)
with 163 cases yearly. Men were aﬀected in 2565 cases and
women in 2686 cases, representing, respectively, 48.8% and
51.2% of cases with a ratio of 0.9.
The average age of patients was 45.3 years with extremes
of 10 days and 98 years. This average was 43.8 years
for women and 46.9 years for men. Figure 1 shows the
distribution of cancers according to sex and age. The most
aﬀected age bracket was 45–54 years for women (21%) and
over 64 years for men (23.2%).4 Journal of Cancer Epidemiology
Table 3: Distribution of cancers by site and age in women.
ICD-10 Site Unk 0–14 15–24 25–34 35–44 45–54 55–64 65+ All %
C 0 – C 0 6 M o u t h 0337 1 0 934 3 9 1 . 5
C 0 7 - C 0 8 S a l i v a r y g l a n d 12697528 3 9 1 . 5
C 9 – C 1 4 P h a r y n x 01262334 2 2 0 . 8
C15 Oesophagus 0 0 2 6 7 8 16 10 49 1.8
C16 Stomach 0 0 5 4 14 30 23 39 115 4.3
C17 Small intestine 0 3 1 4 2 3 0 1 14 0.5
C18–C21 Colon, rectum, anus 0 1 6 8 11 12 9 14 61 2.2
C 2 2 L i v e r 04478739 4 2 1 . 6
C 2 3 - C 2 4 G a l l b l a d d e r , a n d s o f o r t h . 000011125 0 . 2
C 2 5 P a n c r e a s 000102025 0 . 2
C30-C31 Nose, sinuses, and so forth. 0 1 2 0 3 1 3 0 10 0.4
C 3 2 L a r y n x 01003116 1 2 0 . 4
C 3 3 - C 3 4 T r a c h e a , b r o n c h u s a n d l u n g 11002413 1 2 0 . 4
C 3 8 P l e u r a 1012446 1 3 3 1 1 . 2
C40-C41 Bone 1 21 17 13 8 8 10 21 99 3.7
C 4 3 M e l a n o m a o f t h e s k i n 00035683 2 5 0 . 9
C44 Other skin cancers 1 0 6 25 17 20 27 38 134 5.0
C 4 5 M e s o t h e l i o m a 120020005 0 . 2
C46 Kaposi’s sarcoma 4 10 30 34 15 19 8 13 133 5.0
C 4 9 O t h e r s o f t t i s s u e 03202304 1 4 0 . 5
C50 Breast 5 0 17 127 215 196 99 70 729 27.1
C 5 1 V u l v a 03132254 2 0 0 . 7
C 5 2 V a g i n a 04262364 2 7 1 . 0
C53 Cervix 1 0 5 32 77 90 56 41 302 11.2
C54 Uterus 2 1 4 5 15 31 28 26 112 4.2
C 5 6O v a r y 1 1 72 11 61 92 91 61 3 1 3 2 4 . 9
C 5 7 F a l l o p i a n t u b e 100020003 0 . 1
C58 Placenta 0 0 8 17 10 5 3 0 43 1.6
C64 Kidney 0 8 1 4 3 1 1 4 22 0.8
C 6 5 R e n a l p e l v i s 000000011 0 . 0
C 6 7 B l a d d e r 00127452 2 1 0 . 8
C 6 9 E y e 11 461 4 1 25 4 66 2 2 . 3
C 7 0 – C 7 2 B r a i n , n e r v o u s s y s t e m 020001014 0 . 1
C73 Thyroid 1 0 14 8 12 14 10 3 62 2.3
C 7 6 O t h e r a n d u n s p e c i ﬁ e d 001222029 0 . 3
C77–C80 Metastasis 0 1 0 8 10 12 9 1 41 1.5
C 8 1 H o d g k i n d i s e a s e 06196512 3 0 1 . 1
C 8 2 – C 8 5 N o n - H o d g k i n L y m p h o m a 2 3 63 83 31 91 61 41 2 1 7 0 6 . 3
C 9 0 M y e l o m a 000001001 0 . 0
C 9 1 – C 9 5 L e u k a e m i a 01975232 2 9 1 . 1
All sites 24 146 216 422 541 565 384 388 2686 100
The distribution of cancers by site and sex is presented
in Table 1, which shows a predominance of breast can-
cers (14.4%), non-Hodgkin lymphoma (7.8%) and non-
melanoma skin cancers (7.6%). This table shows also that
in men, prostate cancer (12.9%), nonmelanoma skin cancer
(10.4%) and stomach cancer (10.3%) predominated, while
in women, it was breast cancer (27.1%), cervix cancer
(11.2%), and non-Hodgkin lymphoma (6.3%) that were
more observed.
Tables 2 and 3 show, respectively, the distribution of the
diﬀerentsitesofcanceraccordingtoageformenandwomen.
3.2. Histopathological Aspects. The 5251 cases of cancer were
subdivided in 3574 carcinomas (68.1%), 833 hematopoieticJournal of Cancer Epidemiology 5
Table 4: Distribution of cancers by histological nature.
Histological group Histological type Nb∗∗ of cases %
Carcinomas 3574 cases; 68,1%
Adenocarcinomas 2099 40.0
Squamous cell carcinoma 1238 23.6
Carcinoma NOS∗ 155 2.9
Urothelial carcinoma 35 0.6
Medullar carcino ma 31 0.6
Basaloid carcinoma 19 0.4
Hematopoietic tissue Cancers 833 cases;
15.9%
Non-hodgkin lymphoma 663 12.6
Hodgkin disease 97 1.9
Leukaemia 58 1.1
Myeloma 15 0.3
Sarcomas 581 cases; 11.0%
Kaposi sarcoma 225 4.3
Fibrosarcoma 146 2.8
Leiomyosarcoma 38 0.7
Rhabdomyosarcoma 35 0.6
Osteosarcoma 30 0.5
Chondrosarcoma 28 0.5
Liposarcoma 27 0.5
Angiosarcoma 19 0.4
Malignant ﬁbrous histiocytoma 19 0.4
Ewing sarcoma 4 0.1
Sarcoma NOS∗ 10 0.2
Embryonic and placental malignant
tumors 143 cases; 2.7%
Choriocarcinoma 50 1.0
Retinoblastoma 38 0.7
Wilms tumor 19 0.4
Malignant teratoma 10 0.2
Yolk sac tumor 6 0.1
Hepatoblastoma 5 0.1
Seminoma 5 0.1
Glioblastoma 5 0.1
Gonadoblastoma 3 0.0
Other 2 0.0
Other speciﬁed cancers 120 cases; 2.3%
Melanoma 83 1.6
Granulosa tumor 19 0.4
Mesothelioma 7 0.1
Malignant schwannoma 8 0.2
Carcinosarcoma 3 0.0
All 5251 100
∗NOS: not otherwise speciﬁed. ∗∗Nb: Nomber.
tissue cancers (15.9%), 581 sarcomas (11.0%), 143 embry-
onic and placental malignant tumors (2.7%), and 120 other
histological types (2.3%) as shown in Table 4.
3.3. Children Cancers (under 15 Years). The children cancers
were observed in 365 cases representing 7% of all cancers
recorded, with a yearly average of 14.6 cases. Boys were
aﬀected in 218 cases and girls in 146 cases, with a sex ratio
of 1.5. The average age of these children was 8.1 years old.
Histologically, we noted a predominance of lymphomas
(219 cases, 60%) including 102 cases of Burkitt lymphoma,
retinoblastoma (31 cases, 8.5%), and nephroblastoma (17
cases, 4.7%).
4. Discussion
Our study focused on epidemiological and histopathological
analysis of cancers diagnosed during 25 years in Togo.
It brings together all histologically conﬁrmed cases across6 Journal of Cancer Epidemiology
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Figure 1: Distribution of cancers according to age and sex. ∗unk:
unknown.
the country because the laboratory of pathology of CHU-
TOKOIN, is the only one in Togo for all requests of
histopathologicalexamination.Soourstudymustputcancer
in its epidemiological framework in Togo and constitute a
basisfortheestablishmentofacancerregisterinourcountry.
We then observed during our study period 5251 cases
of cancers proved histologically with a yearly average of
210 cases. This value is comparable to those observed in
most African countries particularly Burkina Faso, but clearly
inferior to those of western countries [1, 5, 6]. These
diﬀerences are in part related to the unequal distribution
of cancer throughout the world but also to the size of the
populations investigated. They could also be explained by
the weak frequentation of the health centers in developing
countries, and where women are more aﬀected by cancer.
The sex ratio in our study is similar to those observed in
Uganda, Algeria, and Brazil [1, 5]. This female predomi-
nance is even more pronounced in some countries such as
Cameroon and Nigeria with a sex ratio of 0.7 [5, 7], contrary
to the observations made in European countries or Asia
where there is a clear male predominance [1, 8]. This female
predominance of cancer in our countries is explained by the
large proportion of breast and cervix cancers.
The average age of our patients is comparable to that
of developing countries but lower than those observed in
developed countries. This would be related to the longer life
expectancy of these countries. The most common cancers
for both sexes in our study (breast cancer, non-Hodgkin
lymphoma, and nonmelanoma skin cancer) were diﬀerent
fromthoseestimatedbyIARCGlobocanwherebreast,cervix
uteri, and prostate predominated [9]. Moreover Globocan
estimated prostate and liver cancers the two main cancers in
men. These estimations are diﬀerent from our observations
and may be due to the case of many patients who, after
having wasted an invaluable time near the healers, consult
the medical practitioner only at the ﬁnal stage of their illness.
Forthesecases,mostpractitionershadfoundanysamplesfor
histological conﬁrmation useless. It was mainly the case of
livercancerthataccountonlyfor2.2%ofcases(11thoverall).
This frequency of liver cancer in our study reﬂects a little
the real impact of this cancer in Togo. The diagnosis of the
disease is most often based on clinical ﬁndings, especially
when patients come to a very advanced stage of their disease.
So,thehistologicaldiagnosisofsuchpatientsdoesnotappear
in our records and this would let think that liver cancer
is rare in Togo, compared to some African countries like
Mali, Cameroon, and Senegal, where liver cancer represents
respectively 42.1%, 38.2%, and 36.8% of recorded cancers
and where it occupies the ﬁrst rank [5]. Indeed, Africa
is a region with high incidence of liver cancer, but with
very large variations from one country to another [3, 5, 6].
The establishment of a cancer register will help to catch
up these cases for a better cancer assessment in Togo. For
women, breast and cervix uteri cancers were more frequent
corroborating data from the literature [1, 5, 9]. In our study
we observed a decrease of cancer incidence in the last ten
years. This may be due to sensitization on cancer prevention.
We have no data on the survival estimation from cancer as it
was a retrospective laboratory work.
Histologicallywenotedapredominanceofcarcinomasas
in the study of Goumbri-Lompo in Burkina Faso where car-
cinomas represented 75.5% of cases [6]. The non-Hodgkin
lymphoma accounted for 12.6% of cases, a value exceeding
thatofworldliterature.Indeed,thenon-Hodgkinlymphoma
represents 2.9% of cancers worldwide, 3.9% of cancers in
Africa, and 5.1% in Sub-Saharan Africa but with signiﬁcant
variations of the frequency from one country to another
[1, 5]. The high incidence of non-Hodgkin lymphoma in
some parts of Africa is linked to infectious causes including
viralandparasiticinfectionimplicatedinthegenesisofsome
ofthenon-HodgkinlymphomaincludingBurkittlymphoma
[10, 11]. Burkitt lymphoma accounted in fact for the most
common children cancer, followed by retinoblastoma and
Wilms tumor, as in most African countries [12–14].
5. Conclusion
Our retrospective study aimed to describe the epidemio-
logical and histopathological aspects of cancers in Togo. It
covered 5251 cases occurring at a mean age of 45.3 years with
a slight female predominance. The most frequent cancers
in this study were those of prostate for men and breast for
women. For children, it was essentially Burkitt lymphoma
and retinoblastoma. The high incidence of cancers in Togo
shows the importance of this study and emphasizes on the
necessity of the establishment of a cancer register, which is
necessary to a national policy of prevention and ﬁght against
cancer in Togo.
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